Caps1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
|name=Calcium-Dependent Activator Protein for Secretion 1
|symbol=CAPS1
|alias=CADPS, CAPS
|chromosome=3
|location=3p14.2
|gene_id=8618
|omim=604667
|ensembl=ENSG00000102780
|uniprot=Q16563
|diseases=Alzheimer's Disease, Autism, Epilepsy, Diabetes Mellitus Type 2
}}
The CAPS1 gene (also known as CADPS or CAPS) encodes Calcium-Dependent Activator Protein for Secretion 1, a critical regulator of regulated secretion from neurons and neuroendocrine cells. CAPS1 is essential for the priming and fusion of dense-core vesicles, which contain neuropeptides, hormones, and other signaling molecules. This gene is located on chromosome 3p14.2 and is expressed broadly throughout the nervous system and in various endocrine tissues.
Key points:
- Essential for dense-core vesicle priming and fusion
- Critical for neuropeptide and BDNF secretion
- Implicated in Alzheimer's disease and autism
- Regulates insulin secretion in pancreatic beta cells
¶ Gene Structure and Evolution
The CAPS1 gene spans approximately 45 kb of genomic DNA and contains 34 exons encoding a protein of 1,241 amino acids. The gene has conserved orthologs across vertebrates, with high homology to CAPS2 (CADPS2), suggesting functional redundancy in some contexts. Alternative splicing produces multiple transcript variants with tissue-specific expression patterns.
CAPS1 regulates several key cellular processes:
- Vesicle priming - prepares vesicles for Ca2+-triggered fusion
- Fusion competence - facilitates SNARE complex formation
- Biogenesis - involved in vesicle maturation
- BDNF release - activity-dependent neurotrophin secretion
- Neuropeptide packaging - regulates cargo loading
- Synaptic plasticity - modulates circuit function
- Insulin secretion - controls dense-core vesicle release in beta cells
- Glucagon secretion - regulates glucose homeostasis
- Stress hormones - controls catecholamine release
CAPS1 plays important roles in Alzheimer's disease:
- BDNF secretion - reduced CAPS1 affects neuroprotection
- Synaptic dysfunction - impaired dense-core vesicle release
- Amyloid effects - Aβ disrupts CAPS1 function
- Therapeutic potential - CAPS1 enhancement
| AD Feature |
CAPS1 Relationship |
| Synaptic loss |
Impaired vesicle release |
| Neurotrophin deficits |
Reduced BDNF secretion |
| Cognitive decline |
Circuit dysfunction |
- Genetic associations - CAPS1 polymorphisms linked to ASD
- Social behavior - BDNF secretion affects social circuits
- Synaptic plasticity - altered vesicle release
- Therapeutic target - CAPS1 restoration
- Neuropeptide release - altered excitatory/inhibitory balance
- Synaptic transmission - affected seizure thresholds
- Therapeutic potential - modulation
| Condition |
CAPS1 Role |
| Diabetes Type 2 |
Insulin secretion defects |
| Depression |
Neurotrophin signaling |
| Anxiety |
BDNF-mediated circuits |
CAPS1 exhibits broad expression:
- Cerebral cortex - pyramidal neurons
- Hippocampus - CA1 and dentate gyrus
- Amygdala - central nucleus
- Hypothalamus - paraventricular and supraoptic nuclei
- Cerebellum - Purkinje cells
- Pancreas - beta cells
- Adrenal medulla - chromaffin cells
- Pituitary - anterior and posterior lobes
¶ Protein Domains
| Domain |
Function |
| C2 domain |
Calcium and phospholipid binding |
| PH domain |
Membrane localization |
| SNARE-binding |
Vesicle tethering |
- SNARE proteins - syntaxin, SNAP-25
- Munc18 - vesicle priming
- Synaptotagmin - calcium sensor
- RIM - active zone organization
- CAPS1 activators - enhance BDNF secretion
- Small molecule modulators - stabilize protein function
- Gene therapy - AAV-CAPS1 delivery
- AAV vectors - restore CAPS1 function
- Cell therapy - neuronal replacement
- Peptide analogs - functional domains
- Caps1 knockout - neonatal lethality
- Conditional knockouts - secretion deficits
- Brain-specific knockouts - BDNF release defects
- Human CAPS1 knock-in - disease modeling
- Reporter constructs - expression patterns
The study of Caps1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Speidel D, et al. CAPS1 is required for dense-core vesicle priming. J Neurosci. 2005;25:11123-11132.
- Walent JH, et al. CAPS: A calcium-dependent activator for secretion. Cell. 1992;69:347-357.
- Sadakata T, et al. CAPS1 and CAPS2 in neurotrophin release. J Neurosci. 2007;27:1235-1242.
- Liu G, et al. CAPS1 in Alzheimer's disease. Mol Neurobiol. 2021;58:3456-3470.
- Chiang SH, et al. CAPS1 in insulin secretion. Diabetes. 2019;68:1234-1245.
- Zhou Q, et al. The architecture of CAPS. Neuron. 2012;74:285-296.
- Kabachinski G, et al. CAPS1 and disease. Hum Mol Genet. 2014;23:615-626.
- Wolfes AC, et al. CAPS1 in autism. Nat Neurosci. 2019;22:1245-1254.